Jeffrey Nau
About
In The Last Decade
Jeffrey Nau
24 papers receiving 351 citations
Peers
Comparison fields: 5 of 38
- Ophthalmology 298
- Radiology, Nuclear Medicine and Imaging 225
- Public Health, Environmental and Occupational Health 87
- Molecular Biology 83
- Immunology and Allergy 62
Countries citing papers authored by Jeffrey Nau
This map shows the geographic impact of Jeffrey Nau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey Nau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey Nau more than expected).
Fields of papers citing papers by Jeffrey Nau
This network shows the impact of papers produced by Jeffrey Nau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey Nau. The network helps show where Jeffrey Nau may publish in the future.
Co-authorship network of co-authors of Jeffrey Nau
This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey Nau. A scholar is included among the top collaborators of Jeffrey Nau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey Nau. Jeffrey Nau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 5 | |
| 3 | 6 | |
| 4 | 7 | |
| 5 | ONSET-2 Phase 3 Study of OC-01 Nasal Spray for the Treatment of Dry Eye Disease | 2 |
| 6 | 14 | |
| 7 | 27 | |
| 8 | Analysis of 24 month data from the HARBOR study indicates that anti-therapeutic antibodies status had no significant impact on the treatment response to ranibizumab | 2 |
| 9 | 8 | |
| 10 | 13 | |
| 11 | 49 | |
| 12 | 32 | |
| 13 | 16 | |
| 14 | 5 | |
| 15 | 24 | |
| 16 | 2 | |
| 17 | 39 | |
| 18 | A Phase II, Multi–Center, Randomized, Controlled, Masked Study of the Effects of Squalamine Lactate in Combination With Visudyne® in Patients With Subfoveal Choroidal Neovascularization Associated With Age–Related Macular Degeneration | 4 |
| 19 | 1 | |
| 20 | 6 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.